CSL Earnings Hit by Impairments as Transformation Drive and Buy-Back Accelerate

CSL ( (AU:CSL) ) has provided an announcement.

CSL reported half-year underlying NPATA of US$1.9 billion, down 7% in constant currency, with reported net profit plunging 81% to US$401 million as government policy changes, restructuring costs and US$1.1 billion in impairments weighed on results. Revenue fell 4% to US$8.3 billion, driven by weaker immunoglobulin and albumin sales, including a sharp hit from Chinese policy changes and Medicare Part D reforms, although haemophilia products and the newly launched ANDEMBRY posted solid growth.

Despite the earnings slump, CSL said its transformation program is progressing well, having already achieved about 60% of targeted FY26 cost savings through R&D and infrastructure reductions and integration of Behring and Vifor commercial teams. Backed by strong cash flow and a robust balance sheet, the company expanded its share buy-back to US$750 million, committed around US$1.5 billion to expand U.S. plasma manufacturing and maintained FY26 guidance for modest revenue and NPATA growth, underscoring confidence in a stronger second half led by Ig, albumin and new products.

The most recent analyst rating on (AU:CSL) stock is a Hold with a A$198.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

More about CSL

CSL Limited is a global biotechnology company focused on plasma-derived and recombinant therapies, vaccines and specialty medicines. Through its CSL Behring and CSL Vifor units, the group targets immunology, hematology, nephrology and rare disease markets, with a growing presence in U.S. plasma manufacturing and collaborations in novel coagulation treatments.

Average Trading Volume: 920,389

Technical Sentiment Signal: Sell

Current Market Cap: A$87.57B

For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.